中文

Journal of Shanghai University >

2018 , Vol. 24 >Issue 1: 16 - 20

DOI: https://doi.org/10.12066/j.issn.1007-2861.2005

Precision and Translational Medicine

Interpretation of 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy

Expand
  • Heart Failure Care Unit, Fuwai Hospital, Chinese Academy of Medical Sciences,Beijing 100037, China

Received date: 2018-01-15

  Online published: 2018-03-02

Fold

Abstract

2014 European Society of Cardiology (ESC) Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy (HCM) was published in August, 2014, during the congress of ESC 2014. The guideline focused on the definition, epidemiology, etiology,diagnosis and clinical evaluation, genetic testing and family screening, treatments, follow-up, reproduction and contraception associated with HCM. A brief interpretation of these contents is made in the present article.

Key words： hypertrophic cardiomyopathy (HCM); guideline; interpretation

Cite this article

ZOU Changhong, ZHAO Xuemei, ZHANG Yuhui . Interpretation of 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy[J]. Journal of Shanghai University, 2018 , 24(1) : 16 -20 . DOI: 10.12066/j.issn.1007-2861.2005

References

[1] Elliott P M, Anastasakis A, Borger M A , et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014,35(39):2733-2779.
[2] Maron B J, Mckenna W J, Danielson G K , et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines[J]. Eur Heart J, 2003,24(21):1965-1991.
[3] Gersh B J, Maron B J, Bonow R O , et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. J Am Coll Cardiol, 2011,58(25):2703-2738.
[4] Maron B J, Gardin J M, Flack J M , et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4 111 subjects in the CARDIA study. Coronary artery risk development in (young) adults[J]. Circulation, 1995,92(4):785-789.
[5] Zou Y, Song L, Wang Z , et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8 080 adults[J]. Am J Med, 2004,116(1):14-18.
[6] Maron B J, Olivotto I, Spirito P , et al. Epidemiology of hypertrophic cardiomyopathy related death: revisited in a large non-referral-based patient population[J]. Circulation, 2000,102(8):858-864.
[7] O'mahony C, Jichi F, Pavlou M , et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)[J]. Eur Heart J, 2014,35(30):2010-2020.
Options
Outlines

/

〈 〉